

# NYRx Notice to Providers: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Concurrent Therapy

---

February 18, 2026

Concurrent therapy with multiple Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is associated with an increased risk of gastrointestinal toxicity and minimal improvement in efficacy. Although topical NSAIDs result in lower systemic absorption than oral formulations, no clinical benefit has been established for the combined use of topical and oral NSAIDs.

**Effective February 19, 2026**, NYRx will implement pharmacy clinical edits that limit concurrent use of multiple NSAIDs.

## What Providers Need to Know

- NYRx covers medically necessary, FDA-approved drugs when used for Medicaid-covered indications.

## What Providers Need to Do

- Prescribers should consult current practice guidelines. Concurrent utilization of NSAIDs, will result in a pharmacy claim rejection.
- Pharmacists should review patient drug history and work with prescribers to avoid concurrent utilization of NSAIDs.

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.